A Randomized, Multi-Center, Blinded, Placebo-Controlled Study Of Mapatumumab ([HGS1012], A Fully Monoclonal Antibody To TRAIL-R1) In Combination With Sorafenib As A First-Line Therapy In Subjects With Advanced Hepatocellular Carcinoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Time to Progression
up to 2 years
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
HGS1012-C1103
NCT01258608
December 2010
December 2013
Name | Location |
---|---|
UMDNJ University Hospital | Newark, New Jersey 07103 |
University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
Penn State Hershey Cancer Institute | Hershey, Pennsylvania 17033 |
North Mississippi Hematolgy and Oncology Associates, ltd | Tupelo, Mississippi 38801 |
UPMC Cancer Center- Hillman Cancer Center | Pittsburgh, Pennsylvania 15232 |